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copy and nasal wash specimens from 
patient 4 also were negative for such 
antigens on laboratory testing. This 
underscores the limitations of current 
testing and that the sensitivity of pan-
demic (H1N1) 2009 diagnostic test-
ing remains poor and needs further 
improvement. Thus, in patients sus-
pected of having pandemic (H1N1) 
2009 or in those who are critically 
ill, lower tract respiratory specimens 
should tested to improve diagnostic 
sensitivity, and clinicians should con-
sider using immunoassay and culture 
methods.
All 4 patients described in this 
case series had viral isolates contain-
ing H275Y mutation in the neuramini-
dase gene of pandemic (H1N1) 2009 
virus, which is speciﬁ  cally associated 
with high-level resistance to oseltami-
vir. Increasing data show that immuno-
compromised patients are at increased 
risk for development of drug-resistant 
inﬂ  uenza infections after oseltamivir 
prophylaxis or while receiving osel-
tamivir treatment (6). Fortunately, this 
resistance trait remains rare.
Existing evidence suggests os-
eltamivir-resistant pandemic (H1N1) 
2009 virus is stable and retains simi-
lar transmissibility and virulence as 
the wild-type virus (7). Therefore, 
in immunosuppressed patients, in 
which the inﬂ  uenza mortality rate is 
high, clinicians should also suspect 
drug-resistant inﬂ   uenza infection if 
the patient does not improve. Before 
she died of underlying hematologic 
illness, patient 2 clinically improved 
after treatment with intravenous 
zanamivir (obtained through an 
emergency application for an inves-
tigational–new drug). As reported in 
other studies, pandemic (H1N1) 2009 
virus was found in her nasal washes, 
1 week after she received zanamivir 
for 10 days (8).
Some data suggest that pandemic 
(H1N1) 2009 virus has a predilection 
to affect the lower respiratory tract 
and is associated with more illness 
and death than is seasonal inﬂ  uenza 
(9). All 4 case-patients with in this se-
ries developed dyspnea, and 3 of the 
4 ultimately died of refractory respira-
tory failure. Our observations suggest 
that oseltamivir-resistant pandemic 
(H1N1) 2009 virus is also associated 
with poor prognosis and may retain 
the same tropism for lower respiratory 
tract involvement as wild type.
These case-patients illustrated the 
complexity of the diagnosis and man-
agement of such infections in hospi-
talized immunocompromised patients. 
Vigilance and heightened clinical sus-
picion are needed to facilitate early 
diagnosis, treatment and prevention 
measures to limit transmission of pan-
demic (H1N1) 2009 virus or similar 
viral pathogens.
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Acute 
Encephalopathy 
and Pandemic 
(H1N1) 2009 
To the Editor: Since the World 
Health Organization declared a global 
pandemic of inﬂ  uenza  A  pandemic 
(H1N1) 2009 in June 2009, the num-
ber of cases of this strain of inﬂ  uenza 
has steadily risen. Although most cas-
es have been mild, with complete and 
uneventful recovery, multiple cases of 
severe infection with complications, 
including death, have been reported. 
Yet the neurologic complications of 
this virus have been rarely described. 
We read with interest the article by 
Kitcharoen et al. (1) concerning a pa-
tient with encephalopathy associated 
with pandemic (H1N1) 2009, which 
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progressed to produce quadriplegia 
with diffuse sensory loss. In that study, 
however, pandemic (H1N1) 2009 virus 
was not isolated from the patient’s ce-
rebrospinal ﬂ  uid (CSF) or brain tissue 
or detected by reverse transcription–
PCR (RT-PCR). We report a case in 
an adolescent patient with encephal-
opathy-associated pandemic (H1N1) 
2009 that was conﬁ  rmed by real-time 
RT-PCR of CSF.
On November 2, 2009, a previ-
ously healthy 16-year-old girl was ad-
mitted to Asan Medical Center, Seoul, 
South Korea. Five days earlier, she 
had sought care for cough, fever (max-
imum 38.5°C), and mild headache. 
Enzyme immunoassay (SD Bioline 
rapid inﬂ   uenza test; Standard Diag-
nostics Inc., Yongin, South Korea) of 
a nasopharyngeal swab was positive 
for inﬂ   uenza virus. Because a large 
outbreak of pandemic (H1N1) 2009 
was concurrent, she was given a pre-
sumptive diagnosis and treated with 
oseltamivir, 75 mg 2×/d, for 5 days. 
However, her headache worsened, and 
she was referred to the hospital.
At admission, her temperature 
was 36.8°C. Examination showed no 
disturbance of consciousness or focal 
neurologic deﬁ  cits except for a severe 
headache. Results of routine labora-
tory tests, including serologic tests 
for HIV, were negative. Real-time 
RT-PCR of a nasopharyngeal swab at 
admission was negative for pandemic 
(H1N1) 2009 virus; a serologic test for 
this virus was not performed. A mag-
netic resonance imaging (MRI) scan 
of the patient’s brain at admission is 
shown in the Figure, panel A. Exami-
nation of CSF showed 0 cells/mm3, 
protein 35.4 mg/dL, glucose 48 mg/
dL; blood glucose level was 49%. No 
bacteria or fungi were isolated from 
CSF, but pandemic (H1N1) 2009 vi-
rus was detected by real-time RT-PCR 
(Roche Diagnostics, Mannheim, Ger-
many). On the basis of the MRI and 
RT-PCR results, we diagnosed enceph-
alopathy-associated pandemic (H1N1) 
2009 infection. By hospital day 3, her 
headache and respiratory symptoms 
had improved, and she was discharged 
on day 10 without headache or other 
neurologic signs. A follow-up brain 
MRI, obtained 1 month later, is shown 
in the Figure, panel B.
Several hypotheses have been 
proposed regarding the pathogen-
esis of inﬂ  uenza-associated acute en-
cephalopathy (IAAE) (2): the most 
straightforward is that it is caused by 
viral infection of the central nervous 
system. The isolation of inﬂ  uenza vi-
rus from the CSF of living patients (3) 
(or its detection by RT-PCR) and from 
brain tissue of patients who have died 
(4) supports this hypothesis. More fre-
quently, however, inﬂ  uenza virus has 
not been detected in the CSF or brains 
of affected patients despite thorough 
attempts. Thus, other possible meth-
ods for the assessing the pathogenesis 
of IAAE have been proposed: elevated 
concentrations of several cytokines 
such as interleukin (IL)–6, tumor ne-
crosis factor (TNF)–α, and soluble 
TNF receptor-1; or determination of 
renal and hepatic dysfunction (2). Al-
though IAAE in adults and children 
was reported during the pandemic 
(H1N1) 2009 pandemic (1,5–8), this 
virus was not detectedby virus isola-
tion or RT-PCR in CSF and brain tis-
sue of these patients. The virus was 
detected in CSF of an infant 3 months 
of age with IAAE (8); however, the 
virus may have been found in CSF be-
cause of the presence of blood from a 
traumatic lumbar puncture. 
The absence of pleocytosis and 
the normal protein and glucose levels 
in CSF from the patient described here 
were noteworthy. Previous reports 
showed that leukocyte counts within 
normal limits (70%–90%) were found 
in CSF of patients with IAAE and sea-
sonal inﬂ  uenza infection (9,10). Recent 
publications on IAAE and concurrent 
pandemic (H1N1) 2009 virus infection 
also reported no increase in CSF leu-
kocyte count and protein level (1,5,7). 
Therefore, absence of CSF pleocytosis 
and protein levels within normal limits 
are common with IAAE.
The diagnosis of IAAE in the pa-
tient reported here is probable, based 
on positive real-time RT-PCR results 
from CSF examination and brain MRI 
ﬁ   ndings. However, some limitations 
should be mentioned. First, a positive 
RT-PCR result could have resulted 
from contamination associated with 
clinical procedures and laboratory 
assays. Nonetheless, we believe that 
the lumbar puncture was done asepti-
cally and that the real-time RT-PCR 
performed in the hospital’s clinical 
microbiologic laboratory was reliable. 
Second, the brain MRI ﬁ  ndings were 
also nonspeciﬁ  c andcould be associ-
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Figure. Magnetic resonance imaging (MRI) scans of case-patient’s brain. A) MRI at hospital 
admission shows ill-deﬁ  ned T2 changes in both cerebellar hemispheres, periventricular 
white matter, and the pons. B) MRI of the brain 1 month later, showing nearly complete 
disappearance of the changes observed at admission.LETTERS
ated with hypoxia, edema, or other 
unknown processes. However, the 
patient had no history of hypotensive 
episodes, hypoxemia, abnormal meta-
bolic and toxic processes, and other in-
fectious disease. In conclusion, IAAE 
with pandemic (H1N1) 2009 may be 
caused by direct viral infection of the 
CNS and, although its pathogenesis 
is not clear, physicians should remain 
alert to this possibility.
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Oseltamivir-
Resistant Pandemic 
(H1N1) 2009 
Treated with 
Nebulized Zanamivir 
To the Editor: In late November 
2009, a 3-year-old immunocompro-
mised boy experienced an upper respi-
ratory tract infection caused by inﬂ  u-
enza A pandemic (H1N1) 2009 virus, 
as demonstrated by a positive result for 
real-time PCR on a nasal swab speci-
men. His medical history was notable 
for a congenital intracardiac tumor; an 
ABO–incompatible heart transplant 
at 2 months of age; and an Epstein-
Barr virus–related humoral rejection 
20 months later that was treated with 
anti-CD20 and plasmapheresis and 
continuous immunosuppressive ther-
apy with tacrolimus and everolimus. 
Thus, a 5-day regimen of oseltamivir 
treatment was undertaken, and the pa-
tient’s clinical signs improved.
However, 3 days after drug treat-
ment was suspended, the child had a 
relapse and exhibited fever, cough, 
and mild respiratory distress. The 
patient had ﬁ  ne crackles in the left 
posterior basal lung, normal oxygen 
saturation, and an inﬁ   ltrate in the 
left basal lung, observed on chest 
radiograph. Infection with pandemic 
(H1N1) 2009 virus was conﬁ  rmed. 
He was then transferred to an isolated 
ward of the pediatric department, and 
oseltamivir treatment was again initi-
ated and dosages of immunosuppres-
sive drugs were reduced. However, 
no clinical or virologic responses 
were observed during the 3 weeks of 
drug administration.
Over the next month, the oral 
dosage of oseltamivir was increased 
twice, without substantial effects on 
clinical course and viral clearance 
of the infection (Figure). Because 
of persistence of infection, the viral 
neuraminidase gene was sequenced, 
which showed the H275Y mutation 
(1). We immediately requested zana-
mivir aqueous solution from GlaxoS-
mithKline (Brentford, UK), and, after 
the approval of the hospital’s ethics 
committee and parents’ consent were 
obtained, nebulized treatment was car-
ried out for 10 days. Fever and respira-
tory symptoms and signs resolved af-
ter 6 days of treatment and progressive 
real-time PCR gave negative results. 
Moreover, at the end of the treatment 
period, chest radiograph did not show 
abnormal ﬁ  ndings, and results of a he-
magglutination-inhibition assay were 
positive for inﬂ  uenza. No zanamivir-
related adverse events were observed, 
except for a mild bronchospasm that 
responded to albuterol.
Another notable point is that the 
clinical course of the disease was not 
severe, although the child was immu-
nocompromised and the infection per-
sisted for almost 2 months. However, 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 11, November 2010  1813 